Vyv Announces Groundbreaking Inactivation And Killing Of Viruses With Its UV-free Antimicrobial Light Technology

Vyv, a female-founded and led health-tech industry leader and pioneer of antimicrobial LED technology, announces the recent independent test results confirming efficacy of its antimicrobial light technology (405nm) for killing* viruses.

Numerous studies have proven the effectiveness of Vyv’s visible light against bacteria, mold, fungi, and yeast.

This recent study has confirmed, through an independent third-party lab, Vyv’s antimicrobial LED products are also effective against non-enveloped viruses, which are the most difficult class of virus to kill*.

“The implications of this are vast because, unlike harmful UV-C light, Vyv’s patented technology can be used continuously and without restriction 24/7 around people, animals, and plants. The recent findings of enhanced efficacy against viruses greatly expand the antimicrobial impact delivered to spaces currently protected with Vyv technology, as well as in new spaces,” said Vyv CEO and co-founder Colleen Costello. “With our overhead LED products, Vyv is already lighting offices, schools and school buses, athletic centers, factories and hospitals. We’re also embedding the same technology in many challenging spaces, including behind elevator buttons, inside consumer products such as humidifiers and bathroom fans, and in airplanes, trains, and public buses.”

Additionally, a recent separate third-party study completed by the Icahn School of Medicine at Mount Sinai also demonstrated efficacy results using ranges of light in the 400-420nm range on inactivating enveloped viruses. With Vyv’s commitment to ongoing research and development advancements of a myriad of new products for healthier spaces, the company will continue to expand its virus testing in the coming months.

The company has announced several high-profile business partnerships and investments with industry front-runners over the past six months. While the COVID-19 global pandemic continues to impact day-to-day life around the world, Vyv has joined forces and expanded development projects with Middleby Corporation, Citi, NJ Transit, Delta Air Lines, Broan-NuTone, Dorel Juvenile and Brilli, among several other well-respected brands. Most recently, Vyv announced a partnership with the Healthcare Association of New York State (HANYS), which is working to advance new approaches to infection control and prevention by dosing interior environments continuously with antimicrobial light to stop and kill* viruses, bacteria, fungi, mold and other organisms.

“Our partners have long understood the threats to global health and wellness. Many of these companies began engineering new solutions with Vyv’s antimicrobial light long before the current pandemic. We’ve been on a path together to bring a new class of continuous microbial protection to address the world’s ever-evolving microbial challenges,” said Costello.

SourceVyv

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”